C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 312—Investigational New Drug ApplicationSubpart B—Investigational New Drug Application (Ind)

21 C.F.R. § 312.21 (2026)

Phases of an investigation

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 16 IN 5Y cited 1991–2026 51citing cases
At a glance

Courts have cited this section in 51 opinions since 1991, 16 of them in the last five years. The most litigated part is subsection (a)(1) (1 case).

An IND may be submitted for one or more phases of an investigation. The clinical investigation of a previously untested drug is generally divided into three phases. Although in general the phases are conducted sequentially, they may overlap. These three phases of an investigation are a follows:

(a) Phase 1. (1) Phase 1 includes the initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. The total number of subjects and patients included in Phase 1 studies varies with the drug, but is generally in the range of 20 to 80.

(2) Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes.

(b) Phase 2. Phase 2 includes the controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects.

(c) Phase 3. Phase 3 studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. Phase 3 studies usually include from several hundred to several thousand subjects.

The 20 cases that cite 21 C.F.R. § 312.21 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENRiegel v. Medtronic, Inc., 552 U.S. 312 (2008).
cites § 312.21 2×cited by 725 cases
Where it cites § 312.21
“21 CFR § 312.21 . After completing the clinical trials, the sponsor files a new drug application containing, inter alia, "full reports of investigations" showing whether the "drug is safe for use and .”
The case’s holding
The Medical Device Amendments preclude state law claims that impose requirements different from, or in addition to, federal requirements regarding a device that received premarket approval.
Later courts cite it for
“360k does not prevent a state from providing a damages remedy for claims premised on a violation of fda regulations; the state duties in such a case 'parallel,' rather than add to, federal requirements.” · 102 citing courts
2
GREENAmericans for Safe Access v. Drug Enf't Admin., 706 F.3d 438 (D.C. Cir. 2013).
cites § 312.21 3×cited by 109 cases
Where it cites § 312.21
“21 C.F.R. 312.21. These studies are designed primarily to explore (Phase II) and to demonstrate or confirm (Phase III) therapeutic efficacy and benefit in patients.”
The case’s holding
An agency's denial of a drug rescheduling petition is not arbitrary or capricious if the decision is supported by substantial evidence.
Later courts cite it for
“under the administrative procedure act, a court may set aside an agency's final decision only if it is 'arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law.” · 11 citing courts
3
GREENKleinman v. Elan Corp., 706 F.3d 145 (2d Cir. 2013).
cites § 312.21 2×cited by 277 cases
Where it cites § 312.21
“See 21 C.F.R. § 312.21 (a). Phase 2 involves further clinical research and study to determine the drug’s efficacy and any “common short-term side effects and risks associated with the drug.”
The case’s holding
Securities laws do not impose an affirmative duty to disclose all material information, but only to make existing statements not misleading.
Later courts cite it for
“where a defendant's competing analysis or interpretation of data is itself reasonable, there is no false statement.” · 6 citing courts
4
GREENFerretti v. Pfizer Inc., 855 F. Supp. 2d 1017 (N.D. Cal. 2012).
cites § 312.21 5×subsections: (a)(1)cited by 19 cases
Where it cites § 312.21
“Plaintiff alleges that she refused to participate in the PanHER program because the program violated the following federal regulations for Investigational New Drugs (“IND”): 21 C.F.R. §§ 312.21 (a)(1); 312.23(a)(5); 312.”
Later courts cite it for
“wrongful termination in violation of public policy is a california common law 19 cause of action providing that 'when an employer's discharge of an employee violates 20 fundamental principles of public policy, the discharged employee may maintain a tort 21 action and recover damages traditionally available in such actions.” · 3 citing courts
5
GREENCity of Edinburgh Council as A v. Pfizer Inc, 754 F.3d 159 (3d Cir. 2014).
cites § 312.21 2×cited by 133 cases
Where it cites § 312.21
“Phase 2 is a controlled clinical study in which various doses of the drug are tested on groups of up to several hundred patients to evaluate preliminary indicia of the drug’s efficacy and safety.”
The case’s holding
Opinions are only actionable under securities laws if they are not honestly believed and lack a reasonable basis.
Later courts cite it for
“(1) a material misrepresentation or omission, (2) scienter, (3) a connection between the misrepresentation or omission and the purchase or sale of a security, (4) reliance upon the misrepresentation or omission, (5) economic loss, and (6) loss causation.” · 28 citing courts
6
GREENNguyen v. New Link Genetics Corp., 297 F. Supp. 3d 472 (S.D. Ill. 2018).
cites § 312.21 3×cited by 15 cases
Where it cites § 312.21
“Defendants' specific statement makes clear that Phase 2 showed a "strong efficacy signal " for the high-dose group.”
The case’s holding
A statement of fact is misleading if it lacks the necessary contextualization of material facts to prevent investors from being misled.
cites § 312.21 2×cited by 28 cases
Where it cites § 312.21
“2008) (describing the FDA approval process); 21 C.F.R. § 312.21 (describing the three phases of clinical investigation).”
The case’s holding
An inference of scienter cannot be drawn from suspicious stock sales by some defendants if other defendants did not trade and no explanation exists for differing knowledge (scienter).
Later courts cite it for
“allegations of merely unreasonable conduct do not sufficiently plead scienter” · 3 citing courts
8
GREENBrennan v. Zafgen, Inc., 853 F.3d 606 (1st Cir. 2017).
cites § 312.21 1×cited by 32 cases
Where it cites § 312.21
“3d at 39 ; see also 21 C.F.R. § 312.21 . Each phase “requires the company to test the drug on a broader population and results in more stringent monitoring and evaluation.”
The case’s holding
A complaint lacking direct evidence of scienter must rely on indirect evidence that is sufficient to raise a strong inference of fraudulent intent.
Later courts cite it for
“where a complaint is devoid of any direct-evidence allegations, the indirect-evidence allegations in the complaint will need to do more work to carry the burden of raising a 'strong inference of scienter' on their own.” · 3 citing courts
9
GREENGrundberg v. Upjohn Co., 813 P.2d 89 (Utah 1991).
cites § 312.21 2×cited by 57 cases
Where it cites § 312.21
“1991); 21 C.F.R. § 312.21 (1990). If the FDA approves the IND, the drug's sponsor may gather data on clinical safety and efficacy needed for a New Drug Application ("NDA"), the formal license application.”
The case’s holding
FDA-approved prescription drugs are unavoidably unsafe as a matter of law, exempting manufacturers from strict liability for design defects if the drug is properly prepared and adequately warned.
Later courts cite it for
“there are three types of product defects: manufacturing flaws, design defects, and inadequate warnings regarding use.” · 3 citing courts
cites § 312.21 2×cited by 22 cases
Where it cites § 312.21
“” 21 C.F.R. § 312.21 (a). It takes approximately one year to conduct Phase I testing.”
The case’s holding
The Due Process Clause protects the right of terminally ill patients to make informed decisions regarding the use of investigational drugs to potentially prolong life.
Later courts cite it for
“that the decision to assume ... known or unknown risks be left to the terminally ill patient and not to the fda.” · 2 citing courts
11
GREENAG Funds, L.P. v. Sanofi, 87 F. Supp. 3d 510 (S.D.N.Y. 2015).
cites § 312.21 1×cited by 71 cases
Where it cites § 312.21
“” 21 C.F.R. § 312.21 (c). Accordingly, this step “can only be taken *534 after there have been positive Phase 2 results sufficient to satisfy both business and regulatory interests.”
The case’s holding
Publicly stated interpretations of clinical study results are opinions rather than actionable facts because reasonable persons may disagree on data analysis and result interpretation.
Later courts cite it for
“courts have repeatedly held 'publicly stated interpretations of the results of various clinical studies' to be 'opinions' because 'reasonable persons may disagree over how to analyze data and interpret results, and neither lends itself to objective conclusions.” · 8 citing courts
cites § 312.21 1×cited by 63 cases
Where it cites § 312.21
“See 21 C.F.R. § 312.21 . Each phase requires the company to test the drug on a broader population and results in more stringent monitoring and evaluation.”
The case’s holding
A statement is not intentionally misleading if the defendant lacks sufficient information at the relevant time to form an intent not to disclose certain information.
Later courts cite it for
“a statement cannot be intentionally misleading if the defendant did not have sufficient information at the relevant time to form an evaluation that there was a need to disclose certain information and to form an intent not to disclose it.” · 9 citing courts
13
GREENHirtenstein v. Cempra, Inc., 348 F. Supp. 3d 530 (M.D.N.C. 2018).
cites § 312.21 4×cited by 2 cases
Where it cites § 312.21
“¶¶ 39-43 ); see 21 C.F.R. § 312.21 . Each phase of clinical testing is designed to gather information on the safety and efficacy of the drug in human subjects.”
Later courts cite it for
“statements of opinion are generally actionable only if the plaintiff establishes that the statement was objectively false and the issuer lacked a rational belief in the veracity of the statement at the time it was made.” · 1 citing court
cites § 312.21 3×cited by 32 cases
Where it cites § 312.21
“See 21 C.F.R. § 312.21 . Phase I involves the initial introduction of a new drug into human subjects.”
15
GREENIn re Elan Corp. Sec. Litig., 543 F. Supp. 2d 187 (S.D.N.Y. 2008).
cites § 312.21 1×cited by 27 cases
Where it cites § 312.21
“(¶ 93); see also 21 C.F.R. § 312.21 . During Phase I, the drug is administered to a small number of healthy participants in order to determine the proper dosage of the drug, to characterize its metabolism and excretion, and to identify acute side effects.”
Later courts cite it for
“even if scientists suspected that the fidelis lead might cause severe adverse events and defendants knew of these suspicions, these facts would not have required defendants to conclude that these effects were real before such a relationship was established using accepted statistical methods and standards of proof.” · 2 citing courts
16
GREENLerner v. Nw. Biotherapeutics, 273 F. Supp. 3d 573 (D. Md. 2017).
cites § 312.21 1×cited by 10 cases
Where it cites § 312.21
“” 21 C.F.R. § 312.21 (a). Phase II involves studies that are “typically well-controlled,” to determine the effectiveness of the drug on “patients with the disease or condition under study.”
Later courts cite it for
“courts have routinely held that corporate executives' access to information and internal affairs is not enough to demonstrate scienter under the pslra.” · 2 citing courts
cites § 312.21 1×cited by 58 cases
Where it cites § 312.21
“See 21 C.F.R. § 312.21 (b). FDA approval, however, is not a prerequisite for finding a compound useful within the meaning of the patent laws.”
The case’s holding
Utility in pharmaceutical inventions includes the expectation of further research and development and does not require human testing to satisfy patent law requirements.
Later courts cite it for
“usefulness in patent law, and in particular in the context of pharmaceutical inventions, necessarily includes the expectation of further research and development.” · 3 citing courts
18
GREENIn re Neurotrope, Inc. Sec. Litig., 315 F. Supp. 3d 721 (S.D. Ill. 2018).
cites § 312.21 2×cited by 3 cases
Where it cites § 312.21
“21 C.F.R. § 312.21 ; see also The FDA's Drug Review Process: Ensuring Drugs are Safe and Effective, https://www.”
19
GREENSandoz Inc. v. Amgen Inc., 773 F.3d 1274 (Fed. Cir. 2014).
cites § 312.21 1×cited by 17 cases
Where it cites § 312.21
“See 21 C.F.R. § 312.21 (Phase III trials “usually include from several hundred to several thousand subjects”).”
Later courts cite it for
“we have assessed 'immediacy' by considering how far in the future the potential infringement is, whether the passage of time might eliminate or change any dispute, and how much if any harm the potential infringer is experiencing, at the time of suit, that an adjudication might redress.” · 3 citing courts
20
GREENFrater v. Hemispherx Biopharma, Inc., 996 F. Supp. 2d 335 (E.D. Pa. 2014).
cites § 312.21 1×cited by 14 cases
Where it cites § 312.21
“See 21 C.F.R. § 312.21 . This includes the design, conduct, and analysis of clinical trials.”
Later courts cite it for
“when the fda tells a company about problems with a product, and the company nonetheless continues to make confident predictions about a product, courts have inferred scienter and falsity.” · 2 citing courts

Show all 51 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199120082026

One bar per year. Tallest: 5 cases in 2014. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
Del. Ch.6D.C. Cir.4S.D.N.Y.41st Cir.3Fed. Cir.3D. Mass.3D.N.J.3E.D. Pa.3

The 8 courts with the most citing cases, of 24 courts in all.

By subsection
(a)(1)1 case
Ferretti v. Pfizer Inc., 855 F. Supp. 2d 1017 (N.D. Cal. 2012).“Plaintiff alleges that she refused to participate in the PanHER program because the program violated the following federal regulations for Investigational New Drugs (“IND”): 21 C.F.R. §§ 312.21 (a)(1); 312.23(a)(5); 312.”

Show all 51 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com